GLUCAGON-LIKE peptide-1 (GLP-1) receptor agonists have significant benefits for kidney and cardiovascular outcomes in people with and without diabetes, according to researchers from The George Institute for global health and published in The Lancet Diabetes & Endocrinology.
The large and comprehensive analysis of the popular diabetes and obesity drugs, including semaglutide (Ozempic/Wegovy), dulaglutide (Trulicity) and liraglutide (Victoza), found that GLP-1 receptor agonists reduced the risk of kidney failure by 16% and the worsening of kidney function by 22%.
The analysis also confirmed previous findings that GLP-1 receptor agonists protect cardiovascular health, with a 14% reduction in the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke, compared to placebo.
Death by any cause was 13% lower among patients treated with GLP-1 receptor agonists.
The results were particularly important for people with chronic kidney disease, which affects one in ten people worldwide and is the tenth leading cause of death.
The combined reduction in the risk of kidney failure, worsening kidney function, and death due to kidney disease was 19%. KB
Read the full paper HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Nov 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Nov 24
